✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Exit Type◇ research
Unknown
Subsequent Funding◇ research
$26,400,000
Received VC Funding◇ research
Yes
Current Employees◇ research
50
Peak Employees◇ research
50
SBIR/STTR Awards◇ research
$2,999,965
Used Crowdfunding◇ research
—
Notes
KY Angel PDF shows $2,102,000 actual KAITC investment across 5 entries (2017-2018). Bexion announced an increase of its Series B financing to $25MM on 2019-04-30. In 2024 it announced a $1.4M Michael J. Fox Foundation grant. LinkedIn shows company size 11-50 and Covington HQ. Earlier public reporting notes a $2.9M NCI SBIR Bridge Award in 2013.
[Deep research 2026-04-11] November 2024: Company completed enrollment in Phase 1b/2 ASIST study for metastatic colorectal cancer and participated in Jefferies London Healthcare Conference. Active clinical development continues with ongoing trials for BXQ-350 targeting solid tumors and chemotherapy-induced peripheral neuropathy. Current leadership includes Jim Beach (CEO/President) and Joyce LaViscount (CFO). Source: https://bexionpharma.com
Last updated: Apr 11, 2026 · Evidence score: 5/5